Blood Brain Barrier Technologies Market
Blood Brain Barrier Technologies Market
Blood Brain Barrier Technologies Market to Reach US$ 8.9 Bn by 2032, driven Rising prevalence of neurological diseases such as Alzheimer’s disease, Parkinson’s disease, and brain tumors: Global Insight Services
New York, January 2023: According to a new research study by Global Insight Services (GIS), the global Blood Brain Barrier Technologies Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 8.9 Billion by 2032.
The blood brain barrier protects the brain against disease-causing pathogens/toxins that may be present in the blood. It blocks the passage of foreign substances entering the brain tissue. It also blocks the passage of life-saving drugs used to treat neurodegeneration and neuroinflammation events. Thus, the technologies used to deliver drugs across blood brain barrier are different than the technologies used to deliver drugs to other body part.
Request Sample Pages of this Research Report:
Blood Brain Barrier Technologies Market: Key Trends and Drivers
Growing awareness regarding neurological disorders, increasing healthcare expenditure, advancements in medical technology, and increasing investment in blood-brain barrier technology development are some key factors driving market revenue growth. Blood-brain barrier plays an essential role in protecting the brain from harmful compounds and blood-borne disorders. It blocks the flow of compounds from circulatory systems to the Cerebrospinal Fluid (CSF) or brain by exchanging particular components controlled by BBB or blood CSF barrier. This makes treatment for brain disorders complex due to the specialized uptake of drugs by the blood-brain barrier. Recent advancements in drug delivery techniques enable drugs to be transferred directly to cerebrospinal fluids. There are several approaches to create a passage for delivering drugs to the brain such as passive diffusion and bispecific antibody RMT approach, Trojan horse approach, and increasing permeability. In Trojan horse approach, the drug is merged to a molecule that is able to cross the blood-brain barrier through a transporter protein.
Blood Brain Barrier Technologies Market: Restraints & Challenges
The complications in brain medication delivery are hindering the market growth. The blood-brain barrier (BBB) has been a great hurdle for brain drug delivery. The BBB in healthy brain is a diffusion barrier essential for protecting normal brain function by impeding most compounds from transiting from the blood to the brain; only small molecules can cross the BBB.
Blood Brain Barrier Technologies Market Report Findings
The increasing permeability segment is likely to hold a dominant Blood Brain Barrier Technologies Market share and grow at a substantial CAGR during the forecast period.
Based on technology, the global blood-brain barrier (BBB) market is segmented into bispecific antibody RMT approach, Passive Diffusion, Trojan horse approach, increasing permeability, passive diffusion, and others. The increasing permeability segment is expected to register the fastest revenue CAGR in the global market over the forecast period. Rise in research & development activities for more advanced drugs & therapeutics for various neurological diseases, and growing significance of increasing permeability mechanism in blood-brain barrier permeation are among the key factors contributing to this segment revenue growth..
The Parkinson disease segment is anticipated to hold a majority of the Blood Brain Barrier Technologies Market size throughout the study period.
Based on application, the global blood-brain barrier (BBB) market is segmented into Alzheimer disease, epilepsy, Parkinson disease, multiple sclerosis, Hunters syndrome, and brain cancer. The Parkinson disease segment accounted for the largest revenue share in the global market in 2020. Rising prevalence of neurological disorders including Parkinson’s disease, growing awareness of early detection and treatment of neurological and CNS disorders, rising demand for advanced drugs and therapeutics for Parkinson’s disease are among the major factors supporting revenue growth of this segment.
The Research Institutes segment is anticipated to hold a majority of the Blood Brain Barrier Technologies Market size throughout the study period.
By end-use, the market is segmented as hospitals, surgical centers, research institutes, and others. The Research Institutes segment would hold a considerable share of the market in 2021, and it is likely to continue its dominance in the market during the forecast period as well. Moreover, increasing healthcare expenditure for long term care patients, growing investment in pharmaceutical research & development, raising awareness for chronic neurological diseases, and growing awareness campaigns for neurological disorders are expected to drive the regional market in the future. Growing research and application in the domain is anticipated to fuel the applications of nanoparticles, thereby driving the drug delivery across the blood-brain barrier market.
The North America region is estimated to exhibit the highest growth rate during the Blood Brain Barrier Technologies Market forecast period.
Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the North America blood-brain barrier (BBB) market accounted for the largest revenue share in the global market in 2020. The regional market revenue growth is majorly attributed to factors such as increasing geriatric population, rising cases of neurological diseases including Alzheimer’s disease, Parkinson’s disease, and Hunter’s syndrome, growing awareness of early diagnosis and treatment of neurological and CNS disorders such as epilepsy/seizures, catalepsy, and brain tumor, and rise in public and private investments in pharmaceutical R&D activities. Presence of advanced healthcare facilities and leading market players in the region, including Bristol-Myers Squibb, Allon Therapeutics, Inc., and Angiochem Inc., further boosts the North America market revenue growth.
Have a question for our analyst:
The global Blood Brain Barrier Technologies Market report includes players are Allon Therapeutics, Inc.Angiochem Inc., Armagen Technologies, Inc., Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., Nanomerics, and F. Hoffman La-Roche AG.., among others.
Recent Developments in the Blood-Brain Barrier Market:
- In November 2022, BioArctic receives new patent in the US for blood-brain barrier transport technology.
- In Feb 2021, Denali Therapeutics completed a phase 1 trial of a broad portfolio of product candidates that are engineered to cross the blood-brain barrier for neurodegenerative diseases.
- In May 2020, Denali Therapeutics unveils blood-brain barrier delivery system.
Blood Brain Barrier Technologies Market Report Coverage
- The report offers a comprehensive quantitative as well as qualitative analysis of the current global Blood Brain Barrier Technologies Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
- A thorough analysis of market trends and restraints is provided.
- Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
- The forecasts in this report are made by examining the recent trends along with future Blood Brain Barrier Technologies Market potential from 2021 to 2031 in terms of revenue.
- Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Blood Brain Barrier Technologies Market are also analyzed.
- Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.
Global Blood Brain Barrier Technologies Market Segmentation
- Bispecific Antibody RMT Approach
- Trojan Horse Approach
- Increasing Permeability
- Passive Diffusion
- Alzheimer Disease
- Parkinson Disease
- Multiple Sclerosis
- Hunter Syndrome
- Brain Cancer
- Surgical centers
- Research Institutes
- North America
- The U.S.
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia-Pacific
- Rest of World
- Latin America
- Middle East
- Allon Therapeutics, Inc.
- Angiochem Inc.
- Armagen Technologies, Inc.
- Bristol-Myers Squibb
- BiOasis Technologies, Inc.
- Sanofi Genzyme
- Cephalon Inc.
- F. Hoffman La-Roche AG..